“These observations indicate important weaknesses in the evidence on Covid-19 serological tests, particularly those being marketed as point-of-care tests,” the authors wrote in the BMJ.
“While the scientific community should be lauded for the pace at which novel serological tests have been developed, this review underscores the need for high-quality clinical studies to evaluate these tools.
“With international collaboration, such studies could be rapidly conducted.”
Commenting on the results, Sanjeev Krishna, Professor of Molecular Parasitology and Medicine at St George’s, University of London, said: “Like most diagnostic tests that need to be developed with urgency, the first products may lack robustness through poor evaluation methodologies or poor test performance, but many tests can be improved with time.
“It is important not to dismiss them from the start, as antibody tests will take their place in the suite of diagnostic tests that are needed to understand and manage the Covid-19 pandemic,
Rochdale Borough Council's chief executive, Steve Rumbelow, said: "We're not at all as bad as Leicester. "The one thing we don't have from PHE, which is crucial in managing the local situation, is the detailed data from the testing. We are lacking the community...
"So there is probably background T-cell immunity in people before they see the coronavirus, and that may be relevant that many people get a pretty asymptomatic disease. "Those T-cells get a bit tired once you're beyond the age of 65 and may not be as effective at...